The role of variability in night-time mean heart rate on the prediction of ventricular arrhythmias and all-cause mortality in implantable cardioverter defibrillator patients

被引:3
作者
Zhao, Shuang [1 ,2 ]
Chen, Keping [1 ,2 ]
Su, Yangang [3 ]
Hua, Wei [1 ,2 ]
Pu, Jielin [1 ,2 ]
Li, Hui [4 ]
Dai, Yan [1 ,2 ]
Tang, Min [1 ,2 ]
Fan, Xiaohan [1 ,2 ]
Zhao, Yunzi [1 ,2 ]
Zheng, Xiaolin [1 ,2 ]
Cai, Chi [1 ,2 ]
Li, Zeyi [1 ,2 ]
Zhang, Shu [1 ,2 ]
机构
[1] Chinese Acad Med Sci, Natl Ctr Cardiovasc Dis, Fuwai Hosp, State Key Lab Cardiovasc Dis,Arrhythmia Ctr, Beijing 100730, Peoples R China
[2] Peking Union Med Coll, Beijing 100021, Peoples R China
[3] Fudan Univ, Zhongshan Hosp, Shanghai Inst Cardiovasc Dis, Dept Cardiol, Shanghai 200433, Peoples R China
[4] Beijing Hui Kang Xin Technol Co Ltd, Beijing, Peoples R China
来源
EUROPACE | 2015年 / 17卷
关键词
Night-time heart rate; Heart rate variability; Implantable cardioverter defibrillator; Ventricular arrhythmias; Home monitoring; SUDDEN CARDIAC DEATH; CARDIOVASCULAR-DISEASE; RISK; TIME; THERAPY;
D O I
10.1093/europace/euv209
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims This study was to use implantable cardioverter defibrillator (ICD) home monitoring (HM) feature to evaluate the role of mean night-time heart rate (MNHR) in the occurrence of ventricular arrhythmias (VAs) and mortality. Methods and results This study retrospectively analysed clinical and ICD device data in 318 ICD patients. Data of the first 30-day MNHR (recorded 02: 00-06: 00 am) by HM were collected. The average and standard deviation of 30-day MNHR (AVHR and SDHR, respectively) were then determined in each patient. The primary endpoint was appropriate ICD treatment of VAs. The secondary endpoint was all-cause mortality. During a mean follow-up period of 32 +/- 10 months, 179 of the 318 patients (56.3%) experienced VAs, 123 patients (38.7%) were treated by ICD shocks, and 37 patients (11.6%) died. The overall SDHR in this study cohort was 4.5 +/- 3.0 bpm. Based on the receiver operating characteristic curve, the cutoff value of SDHR >= 3.685 bpm was identified to predict VAs. In the Kaplan-Meier survival, SDHR >= 3.685 bpm was associated with increased VAs [hazard ratio (HR) = 1.885; 95% confidence interval (CI) = 1.362-2.609; P< 0.001], shock events (HR = 1.637; 95% CI = 1.11-2.414; P = 0.013), all-cause mortality (HR = 2.42; 95% CI = 1.266-4.627; P = 0.008), and the combined endpoints (HR = 1.872; 95% CI = 1.365-2.567; P< 0.001). In univariate and multivariate Cox models (adjusting for clinical factors), SDHR >= 3.685 bpm was still an independent predictor for all endpoints. Conclusion In ICD population, SDHR >= 3.685 bpm was an independent predictor for VAs and all-cause mortality.
引用
收藏
页码:76 / 82
页数:7
相关论文
共 20 条
  • [11] Molnar Janos, 2002, Am J Ther, V9, P99, DOI 10.1097/00045391-200203000-00004
  • [12] Melatonin modulates the light-induced sympathoexcitation and vagal suppression with participation of the suprachiasmatic nucleus in mice
    Mutoh, T
    Shibata, S
    Korf, HW
    Okamura, H
    [J]. JOURNAL OF PHYSIOLOGY-LONDON, 2003, 547 (01): : 317 - 332
  • [13] The role of cardiac autonomic function in hypertension and cardiovascular disease
    Palatini, Paolo
    Julius, Stevo
    [J]. CURRENT HYPERTENSION REPORTS, 2009, 11 (03) : 199 - 205
  • [14] The daily rhythms of genes, cells and organs - Biological clocks and circadian timing in cells
    Schibler, U
    [J]. EMBO REPORTS, 2005, 6 (Suppl 1) : S9 - S13
  • [15] LOW HEART-RATE VARIABILITY AND SUDDEN CARDIAC DEATH
    SINGER, DH
    MARTIN, GJ
    MAGID, N
    WEISS, JS
    SCHAAD, JW
    KEHOE, R
    ZHEUTLIN, T
    FINTEL, DJ
    HSIEH, AM
    LESCH, M
    [J]. JOURNAL OF ELECTROCARDIOLOGY, 1988, 21 : S46 - S55
  • [16] Preprocessing RR interval time series for heart rate variability analysis and estimates of standard deviation of RR intervals
    Thuraisingham, R. A.
    [J]. COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE, 2006, 83 (01) : 78 - 82
  • [17] MORNING PEAK IN VENTRICULAR TACHYARRHYTHMIAS DETECTED BY TIME OF IMPLANTABLE CARDIOVERTER/DEFIBRILLATOR THERAPY
    TOFLER, GH
    GEBARA, OCE
    MITTLEMAN, MA
    TAYLOR, P
    SIEGEL, W
    VENDITTI, FJ
    RASMUSSEN, CA
    MULLER, JE
    [J]. CIRCULATION, 1995, 92 (05) : 1203 - 1208
  • [18] Cardiac Activity and Sympathovagal Balance During Sleep
    Trinder, John
    [J]. SLEEP MEDICINE CLINICS, 2007, 2 (02) : 199 - 208
  • [19] Efficacy and Safety of Automatic Remote Monitoring for Implantable Cardioverter-Defibrillator Follow-Up The Lumos-T Safely Reduces Routine Office Device Follow-Up (TRUST) Trial
    Varma, Niraj
    Epstein, Andrew E.
    Irimpen, Anand
    Schweikert, Robert
    Love, Charles
    [J]. CIRCULATION, 2010, 122 (04) : 325 - U28
  • [20] HRS/EHRA expert consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs): Description of techniques, indications, personnel, frequency and ethical considerations
    Wilkoff, Bruce L.
    Auricchio, Angelo
    Brugada, Josep
    Cowie, Martin
    Ellenbogen, Kenneth A.
    Gillis, Anne M.
    Hayes, David L.
    Howlett, Jonathan G.
    Kautzner, Josef
    Love, Charles J.
    Morgan, John M.
    Priori, Silvia G.
    Reynolds, Dwight W.
    Schoenfeld, Mark H.
    Vardas, Panos E.
    [J]. HEART RHYTHM, 2008, 5 (06) : 907 - 925